Read moreĪ performance obligation is considered. Read moreĬash Flows from Investing Activities. Read moreĮPlex instrument sales also comprised. the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of. Read moreĬash Flows from Financing Activities. The ePlex ® System is an automated in vitro diagnostic device designed to perform multiplexed nucleic acid tests for the simultaneous detection and identification of nucleic acid targets by processing single-use cartridges. Gross profit increased by $39.3 million, or a gross margin increase of seven percentage points during the year ended December 31, 2020, when compared to the prior year, primarily due to the increase in revenue. Roche will buy GenMark Diagnostics, a U.S.-based maker of molecular diagnostic tests in a 1.8 billion deal, the Swiss pharmaceuticals manufacturer said on Monday. However, the complications resulting from the pandemic could result in unforeseen disruptions to our workforce and supply chain (for example, the inability of a key supplier or transportation supplier to source, transport and supply materials to us that are necessary for continued operations) that could negatively impact our operations. These favorable changes were partially offset by an increase in inventory. Gross profit increased by $9.1 million, or a gross margin increase of five percentage points during the year ended December 31, 2019, when compared to the prior year driven entirely by improvements to ePlex gross margin. GenMark Diagnostics is committed to addressing the need to improve patient care through the design and development of comprehensive multiplex panels. The decrease in sales and marketing expense for the year ended December 31, 2020, when compared to the prior year, was primarily driven by decreases of $1.2 million in evaluation kit expense resulting from the commercial launch of our ePlex BCID Panels during the prior year, $1.2 million in travel expense, $0.3 million in bad debt expense, $0.3 million in depreciation expense, and $0.1 million in marketing expense. Other Inside Genmark Diagnostics, Inc.'s 10-K Annual Report: Engineer I, Mechanical/Biomedical Engineering Carlsbad, California Description At GenMark, our work atmosphere is dynamic, fast-paced. (GenMark), is a molecular diagnostics company focused on developing and commercializing multiplex molecular diagnostic solutions designed to enhance patient.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |